Targeting epidermal growth factor receptor variant III: A novel strategy for the therapy of malignant glioma

Adam M. Sonabend, Karen Dana, Maciej S. Lesniak*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations

Abstract

Immunotherapy represents an exciting approach for the treatment of glioblastoma multiforme. The success of this approach depends on the identification of tumor-specific antigens that can then be exploited to target the tumor. One such antigen, the epidermal growth factor receptor variant III (EGFRvIII) is found in up to 50% of malignant gliomas. This molecule is an interesting vaccine candidate since its-expression is tumor specific. Recent preclinical, as well as clinical, studies of EGFRvIII-based vaccines suggest a promising role for immunotherapy of malignant gliomas. This review focuses on vaccines that target EGFRvIII. We review preclinical and clinical data and emphasize the immunological mechanisms involved in its therapeutic effect.

Original languageEnglish (US)
JournalExpert review of anticancer therapy
Volume7
Issue number12 SUPPL.
DOIs
StatePublished - Dec 1 2007

Keywords

  • Clinical trials
  • Epidermal growth factor receptor variant III
  • Glioblastoma multiforme
  • Glioma
  • Immunotherapy
  • Vaccines

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Targeting epidermal growth factor receptor variant III: A novel strategy for the therapy of malignant glioma'. Together they form a unique fingerprint.

Cite this